1. Melmed S, Melmed S: Medical progress: Acromegaly. [Review]
[102 refs]. New England Journal of Medicine 2006, 355:2558-2573.
2. Chanson P, Salenave S: Acromegaly. Orphanet J Rare Dis 2008, 3:17.
3. Colao A, Ferone D, Marzullo P, Lombardi G: Systemic complications
of acromegaly: epidemiology, pathogenesis, and management.
Endocr Rev 2004, 25:102-152.
4. Holdaway IM, Rajasoorya C: Epidemiology of acromegaly. Pituitary
1999, 2:29-41.
5. Pfizer Limited: Somavert: Summary of Product Characteristics.
2004 [http://emc.medicines.org.uk/medicine/14353/SPSOMA
VERT+10mg%2c+15mg+%26+20mg+powder+and+solvent+
for+solution+for+injection/]. Accessed August 2007
6. NHS Centre for Reviews and Dissemination University of York:
Undertaking systematic reviews of research on effectiveness:
CRDs guidance for those carrying out or commisioning
reviews. 4. 2nd edition. 2001.
7. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V,
Lely AJ van der, Dimaraki EV, Stewart PM, Friend KE, Vance ML:
Treatment of acromegaly with the growth hormone-receptor
antagonist pegvisomant. The New England journal of medicine
2000, 342:1171-1177.
8. Lely AJ van der, Hutson RK, Trainer PJ, Besser GM, Barkan AL,
Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML:
Long-term treatment of acromegaly with pegvisomant, a
growth hormone receptor antagonist[see comment]. Lancet
2001, 358:1754-1759.
9. Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V,
Dimaraki E, Stavrou S, Vance ML, Hayden D: Cardiovascular risk
factors in acromegaly before and after normalization of
serum IGF-I levels with the GH antagonist pegvisomant. The
Journal of clinical endocrinology and metabolism 2002, 87:1692-1699.
10. Fairfield WP, Sesmilo G, Katznelson L, Pulaski K, Freda PU, Stavrou S,
Kleinberg D, Klibanski A: Effects of a growth hormone receptor
antagonist on bone markers in acromegaly. Clinical endocrinology
2002, 57:385-390.
11. Biering H, Saller B, Bauditz J, Pirlich M, Rudolph B, Johne A, Buchfelder
M, Mann K, Droste M, Schreiber I: Elevated transaminases during
medical treatment of acromegaly: a review of the German
pegvisomant surveillance experience and a report of a
patient with histologically proven chronic mild active hepatitis.
European Journal of Endocrinology 2006, 154:213-220.
12. Parkinson C, Burman P, Messig M, Trainer PJ, Parkinson C, Burman P,
Messig M, Trainer PJ: Gender, body weight, disease activity, and
previous radiotherapy influence the response to pegvisomant.
Journal of Clinical Endocrinology & Metabolism 2007,
92:190-195.
13. Paisley AN, O'Callaghan CJ, Lewandowski KC, Parkinson C, Roberts
ME, Drake WM, Monson JP, Trainer PJ, Randeva HS, Paisley AN:
Reductions of circulating matrix metalloproteinase 2 and
vascular endothelial growth factor levels after treatment
with pegvisomant in subjects with acromegaly. Journal of Clinical
Endocrinology & Metabolism 2006, 91:4635-4640.
14. Parkinson C, Flyvbjerg A, Trainer PJ: High levels of 150-kDa insulin-
like growth factor binding protein three ternary complex
in patients with acromegaly and the effect of pegvisomantinduced
serum IGF-I normalization. Growth hormone & IGF
research: official journal of the Growth Hormone Research Society and the
International IGF Research Society 2004, 14:59-65.
15. Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ:
Pegvisomant-induced serum insulin-like growth factor-I normalization
in patients with acromegaly returns elevated
markers of bone turnover to normal. The Journal of clinical endocrinology
and metabolism 2003, 88:5650-5655.
16. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M,
Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ: Efficacy of 12-month treatment with the GH receptor antagonist
pegvisomant in patients with acromegaly resistant to
long-term, high-dose somatostatin analog treatment: effect
on IGF-I levels, tumor mass, hypertension and glucose tolerance.
European Journal of Endocrinology 2006, 154:467-477.
17. Jehle S, Reyes CM, Sundeen RE, Freda PU, Jehle S, Reyes CM, Sundeen
RE, Freda PU: Alternate-day administration of pegvisomant
maintains normal serum insulin-like growth factor-I levels in
patients with acromegaly. Journal of Clinical Endocrinology & Metabolism
2005, 90:1588-1593.
18. Feenstra J, de Herder WW, ten Have SM, Beld AW van den, Feelders
RA, Janssen JA, Lely AJ van der, Feenstra J, de Herder WW, ten Have
SMTH: Combined therapy with somatostatin analogues and
weekly pegvisomant in active acromegaly[erratum appears
in Lancet. 2005 May;365(9471):1620]. Lancet 2005,
365:1644-1646.
19. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO,
Hagen C, Orskov H, Jorgensen JOL, Feldt-Rasmussen U, Frystyk J:
Cotreatment of acromegaly with a somatostatin analog and
a growth hormone receptor antagonist. Journal of Clinical Endocrinology
& Metabolism 2005, 90:5627-5631.
20. Pivonello R, Galderisi M, Auriemma RS, De Martino MC, Galdiero M,
Ciccarelli A, D'Errico A, Kourides I, Burman P, Lombardi G: Treatment
with growth hormone receptor antagonist in acromegaly:
effect on cardiac structure and performance. Journal of
Clinical Endocrinology & Metabolism 2007, 92:476-482.
21. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B,
Strasburger CJ, the GPI, Schreiber I, Buchfelder M: Treatment of
acromegaly with the GH receptor antagonist pegvisomant
in clinical practice: safety and efficacy evaluation from the
German Pegvisomant Observational Study. European Journal of
Endocrinology 2007, 156:75-82.
22. Parkinson C, Drake WM, Wieringa G, Yates AP, Besser GM, Trainer
PJ, Parkinson C, Drake WM, Wieringa G, Yates AP: Serum lipoprotein
changes following IGF-I normalization using a growth
hormone receptor antagonist in acromegaly. Clinical Endocrinology
2002, 56:303-311.
23. Parkinson C, Whatmore AJ, Yates AP, Drake WM, Brabant G, Clayton
PE, Trainer PJ, Parkinson C, Whatmore AJ, Yates AP: The effect
of pegvisomant-induced serum IGF-I normalization on
serum leptin levels in patients with acromegaly. Clinical Endocrinology
2003, 59:168-174.
24. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris
PE, Trainer PJ, Lely AJ van der, Vance ML: Glucose homeostasis
and safety in patients with acromegaly converted from longacting
octreotide to pegvisomant. The Journal of clinical endocrinology
and metabolism 2005, 90:5684-5691.
25. Paisley AN, Hayden K, Ellis A, Anderson J, Wieringa G, Trainer PJ:
Pegvisomant interference in GH assays results in underestimation
of GH levels. European Journal of Endocrinology 2007,
156:315-319.
26. Welsh Medicines Partnership: Therapeutic Development
Assessment Pegvisomant (Somavert®). 2007 [http://
www.wales.nhs.uk/sites3/Documents/371/
Enc%203%20WMP%20Pegvisomant%20report.pdf]. Accessed June
2007
27. Bates AS, Van't HW, Jones JM, Clayton RN: An audit of outcome
of treatment in acromegaly. Q J Med 1993, 86:293-299.
28. Orme SM, McNally RJ, Cartwright RA, Belchetz PE: Mortality and
cancer incidence in acromegaly: a retrospective cohort
study. United Kingdom Acromegaly Study Group. J Clin Endocrinol
Metab 1998, 83:2730-2734.
29. Kauppinen-Makelin R, Sane T, Reunanen A, Valimaki MJ, Niskanen L,
Markkanen H, Loyttyniemi E, Ebeling T, Jaatinen P, Laine H: A nationwide
survey of mortality in acromegaly. J Clin Endocrinol Metab
2005, 90:4081-4086.
30. Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS:
Growth hormone and pituitary radiotherapy, but not serum
insulin-like growth factor-I concentrations, predict excess
mortality in patients with acromegaly. J Clin Endocrinol Metab
2004, 89:1613-1617.
31. Rowles SV, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ: Quality
of life (QOL) in patients with acromegaly is severely
impaired: use of a novel measure of QOL: acromegaly quality
of life questionnaire. J Clin Endocrinol Metab 2005,
90:3337-3341.
32. Kauppinen-Makelin R, Sane T, Sintonen H, Markkanen H, Valimaki MJ,
Loyttyniemi E, Niskanen L, Reunanen A, Stenman UH, Kauppinen-
Makelin R: Quality of life in treated patients with acromegaly.
Journal of Clinical Endocrinology & Metabolism 2006, 91:3891-3896.
33. Biermasz NR, van Thiel SW, Pereira AM, Hoftijzer HC, van Hemert
AM, Smit JW, Romijn JA, Roelfsema F: Decreased quality of life in
patients with acromegaly despite long-term cure of growth
hormone excess. J Clin Endocrinol Metab 2004, 89:5369-5376.
34. Hua SC, Yan YH, Chang TC, Hua SC, Yan YH, Chang TC: Associations
of remission status and lanreotide treatment with quality
of life in patients with treated acromegaly. European Journal
of Endocrinology 2006, 155:831-837.
35. Webb SM, Badia X, Surinach NL, Spanish AcroQol Study Group:
Validity and clinical applicability of the acromegaly quality of
life questionnaire, AcroQoL: a 6-month prospective study.
European Journal of Endocrinology 2006, 155:269-277.
36. Trepp R, Everts R, Stettler C, Fischli S, Allemann S, Webb SM, Christ
ER: Assessment of quality of life in patients with uncontrolled
vs. controlled acromegaly using the Acromegaly Quality of
Life Questionnaire (AcroQoL). Clin Endocrinol (Oxf) 2005,
63:103-110.
37. British National Formulary: 2007 [http://www.bnf.org/bnf/]. Accessed
June 2007
38. NHS reference costs 2005-06, Mental Health Services: Inpatient
Data. MHIPA2 adult: acute care 2007. Ref Type: Data File
39. Moore D, Meads C, Roberts L, Song F: The effectiveness of somatostatin
analogues in the treatment of acromegaly. Report
37, West Midlands Health Technology Assessment Collaboration.
Department of Public Health & Epidemiology, University of Birmingham
2001:1-74. Ref Type: Report
40. Cambridgeshire joint prescribing group decision document: Pegvisomant
(Somavert, Pfizer) for treatment of acromegaly. 2006
[http://www.cambsphn.nhs.uk/docu
mentCJPG%20InformatioDecisionPegvisomant%2%20Decision%20Ja
n%202006.doc?pre ventCache=08%2F11%2F2006+16%3A14].
Accessed June 2007
41. Didoni G, Grottol S, Gasco V, Battistini M, Ferone D, Giusti M, Ragazzoni
F, Ruffo P, Ghigo E, Minuto F: Cost-of-illness study in
acromegalic patients in Italy. J Endocrinol Invest 2004,
27:1034-1039.
42. Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, Melmed
S: Lipodystrophy in patients with acromegaly receiving
pegvisomant. J Clin Endocrinol Metab 2008, 93:3515-3518.